Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade on Myeloma Related Bone Disease
NCT01286077Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2009
- Primary completion
- Nov 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 8
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Sep 2009; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01286077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01286077.